

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3629519

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	TRANSFER OF OWNERSHIP
CONVEYING PARTY DATA	
Name	Execution Date
ANACONDA PHARMA	02/25/2015
RECEIVING PARTY DATA	
Name:	BIOTA PHARMACEUTICALS, INC.
Street Address:	2500 NORTHWINDS PARKWAY
Internal Address:	SUITE 100
City:	ALPHARETTA
State/Country:	GEORGIA
Postal Code:	30009
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	8207373
Patent Number:	8440833
Application Number:	14399354
Application Number:	13466530
Application Number:	14655266
CORRESPONDENCE DATA	
Fax Number:	(703)739-9577
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	703-739-4900
Email:	iplaw@stites.com
Correspondent Name:	STITES & HARBISON PLLC
Address Line 1:	1800 DIAGONAL ROAD, SUITE 325
Address Line 2:	B. AARON SCHULMAN
Address Line 4:	ALEXANDRIA, VIRGINIA 22314
ATTORNEY DOCKET NUMBER:	ANACONDA-BIOTA
NAME OF SUBMITTER:	STACY JOHNSON
SIGNATURE:	/Stacy Johnson/
DATE SIGNED:	11/24/2015

Total Attachments: 11

source=BiotaAnacondaAgreementIPsectiononly#page1.tif

source=BiotaAnacondaAgreementIPsectiononly#page2.tif

source=BiotaAnacondaAgreementIPsectiononly#page3.tif

source=BiotaAnacondaAgreementIPsectiononly#page4.tif

source=BiotaAnacondaAgreementIPsectiononly#page5.tif

source=BiotaAnacondaAgreementIPsectiononly#page6.tif

source=BiotaAnacondaAgreementIPsectiononly#page7.tif

source=BiotaAnacondaAgreementIPsectiononly#page8.tif

source=BiotaAnacondaAgreementIPsectiononly#page9.tif

source=BiotaAnacondaAgreementIPsectiononly#page10.tif

source=BiotaAnacondaAgreementIPsectiononly#page11.tif

STOCK PURCHASE AGREEMENT

by and among

BIOTA PHARMACEUTICALS, INC.,

EACH OF THE SHAREHOLDERS OF ANACONDA PHARMA PARTY HERETO,

and

THE HOLDER REPRESENTATIVE

Dated as of February 25, 2015

STOCK PURCHASE AGREEMENT

This STOCK PURCHASE AGREEMENT (this “Agreement”) dated as of February 25, 2015 (the “Agreement Date”) is made and entered into by and among Biota Pharmaceuticals, Inc., a Delaware corporation (“Biota”), certain shareholders of Anaconda Pharma, a French *société par actions simplifiée* (“Anaconda”), party hereto acting severally and not jointly (*non solidairement*) for the purposes hereof (“Sellers” and each, individually, a “Seller”), and the Holder Representative hereunder (collectively, the “Parties”).

WITNESSETH

REDACTED

WHEREAS, the Sellers desire to sell or cause to be sold to Biota, and Biota desires to purchase from the Sellers, on the Closing Date, all of the Shares upon the terms and conditions hereinafter set forth; and

WHEREAS, for certain limited purposes, and subject to the terms set forth herein, the Holder Representative shall serve as a representative of the Sellers.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

REDACTED

“Intellectual Property” shall mean any and all intellectual and industrial property rights and other similar proprietary rights, in any jurisdiction throughout the world, whether registered or unregistered, including all rights pertaining to or deriving from: (a) patents and published or unpublished nonprovisional and provisional patent applications, reissue applications, invention disclosures and records of invention, continuations, continuations-in-part, requests for continued examination and divisions, regardless of country filed or formal name (collectively, “Patents”);

REDACTED

Section 4.19. Intellectual Property.


(a) Section 4.19(a) of the Disclosure Letter sets forth, with respect to all Anaconda Intellectual Property, a complete and accurate list of all (1) Patents and other indicia of ownership of any invention issued or filed with any Governmental Authority , together with all reissues, divisions, continuations, continuations-in-part, revisions, extensions and reexaminations thereof,

IN WITNESS WHEREOF, each party has executed this Agreement or caused this Agreement to be duly executed on its behalf by its officer thereunto duly authorized, all as of the date first above written.


BIOTA PHARMACEUTICALS, INC.

By: Joseph M. Patti
Name: Joseph M. Patti
Title: President and Chief Executive Officer

SELLERS:



Marta Blumenfeld




Moshe Yanniv

Represented by Marta Blumenfeld, his attorney-in-fact



Françoise Thierry

Represented by Marta Blumenfeld, his attorney-in-fact




Michael Botchan

Represented by Marta Blumenfeld, his attorney-in-fact



Ismahane Bali

[Signature Page to Stock Purchase Agreement]



Represented by Aurinvest Partenaires, its
President, itself represented by Michel Demont,
its President






Represented by Jason Loveridge, its attorney-in-
fact



Represented by Marta Blumenfeld, its attorney-
in-fact



Represented by Marta Blumenfeld, its attorney-
in-fact



Represented by Marta Blumenfeld, his attorney-
in-fact

[Signature Page to Stock Purchase Agreement]



Woodform Farm Trust

Represented by Marta Blumenfeld, its attorney-in-fact




Michael Mark

Represented by Marta Blumenfeld, his attorney-in-fact




Amram Rasiel Trust 2002

Represented by Marta Blumenfeld, its attorney-in-fact



Charles Ziering

Represented by Marta Blumenfeld, his attorney-in-fact




Peter Botchan

Represented by Marta Blumenfeld, his attorney-in-fact

[Signature Page to Stock Purchase Agreement]

HOLDER REPRESENTATIVE:

A handwritten signature in cursive script, appearing to read 'Marta Blumenfeld', positioned above a horizontal line.

Marta Blumenfeld

[Signature Page to Stock Purchase Agreement]

Anaconda Pharma Patent Portfolio

Title	Country	Status	US or PCT Serial No	US Patent No. Issue Date	US Expiration Date	International Expiration
BENZOIC ACID DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS	United States of America/ PCT	Patented: US China EP France Japan	12/300,998 371 Date:: November 14, 2008 International Application PCT/EP2007/054483 Filing date: May 18, 2007	8,207,373 June 26, 2012	May 18, 2027 plus Patent Term Adjustment of 699 days= April 16, 2029	Most International patents will expire May 18, 2027 PATENT
HUMAN PAPILLOMA VIRUS INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME	United States of America/ PCT	Patented: US France Japan	12/743,742 371 Date:: July 8, 2010; International Application PCT/EP2008/065915 Filing date: November 20, 2008	8,440,833 May 14, 2013	November 20, 2028 plus Patent Term Adjustment of 232 days (but subject to Terminal Disclaimer so term cannot extend beyond term of US 8,207,373) = April 16, 2029	Most International patents will expire November 20, 2028
PHARMACEUTICAL COMPOSITION OF A PAPILLOMAVIRUS INHIBITOR	United States of America/ PCT	Pending	14/399,354 National Stage of PCT/2013/059,475 International Application Filing date: May 7, 2013		Potential Expiration Date: May 7, 2033	Potential Expiration Date: May 7, 2033
METHOD FOR THE SYNTHESIS OF A HYDRAZINE THAT CAN BE USED IN THE TREATMENT OF THE PAPILLOMA VIRUS	United States of America/ PCT	Pending	US National Stage of PCT/2013/078,035 International Application Filing date: December 27, 2013		Potential Expiration Date: December 27, 2033	Potential Expiration Date: December 27, 2033

Anaconda Pharma Patent Portfolio

Title	Country	Status	US or PCT Serial No Filing Date	US Patent No. Issue Date	US Expiration Date	International Expiration
PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS	United States of America	Pending	13/466,530 May 8, 2012 Divisional application of US 12/300,998 (now US 8,207,373), National Stage of PCT/EP2007/054843 , International Filing Date: May 18, 2007		Potential Expiration Date: May 18, 2027 (subject to possible Patent Term Adjustment and/or terminal disclaimer)	(If foreign equivalents are filed) Potential Expiration Date: May 18, 2027
PATENT						